Reuters logo
BRIEF-Agilis Biotherapeutics announces orphan product designation approval in Europe for the treatment of friedreich ataxia
October 31, 2017 / 2:11 PM / 25 days ago

BRIEF-Agilis Biotherapeutics announces orphan product designation approval in Europe for the treatment of friedreich ataxia

Oct 31 (Reuters) - Agilis Biotherapeutics

* Agilis Biotherapeutics announces orphan product designation approval in Europe for the treatment of friedreich ataxia

* ‍agilis Biotherapeutics says EC granted orphan medicinal product designation in EU to company’s gene therapy product candidate, AGIL-FA​

* ‍agilis Biotherapeutics says company has completed a pre-IND meeting with FDA and is on track to open an IND in 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below